Women account for more than half of the world population, with this ratio especially accentuated on developed countries where women encounter a safer environment to live in. Nevertheless a common global factor is that women are increasingly gaining household and purchasing dominance, hence creating a more powerful market segment.
The Boston Consulting Group estimated that the global incomes of women would grow from $13 trillion to $18 trillion until 2014.
By 2028, the average woman is projected to earn more than the average man in the U.S. (BCG)
Women can suffer from several female-specific conditions. These, although not life-threatening, can result in a major decrease in quality of life and have a serious impact on socio-economic factors. Several companies are developing novel therapies to assist in the management of these conditions; it represents a significant market opportunity as well as improving the quality of life of those affected.
Women and girls continue to face gender-based vulnerabilities that require urgent attention (WHO)
Intravaginal drug delivery has been traditionally restricted to delivery of antinfectives to the local vaginal cavity - administration of local spermicides and cleansing products are a current practice.
Concerted efforts that have been made in the recent past evidenced the significant systemic drug absorption through the vagina, leading to the development of drug products for the management of non-vaginal conditions. To that end, improved delivery systems boosted the use of steroidal hormones as contraceptives or in hormonal substitution therapy.
This supported a rediscovery of the vaginal route as a potential route for the delivery of therapeutically important molecules, biological molecules, vaccines and hormones, mostly in the field of microbicides, mucosal vaccines and therapeutic proteins and peptides.
Despite being a non-invasive route for drug delivery, the vagina has not been extensively explored as compared to other routes. Nowadays, the acceptability of vaginal drug administration by women and doctors is increasing, augmenting interest for this drug delivery route.
Improving women and girls access to antiretroviral therapy, HIV and testing and a range of care, treatment and support services requires specific targets and benchmarks for women and girls. (WHO)